This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Extermann, M. Articles by Lyman, G. H. Search for Related Content PubMed PubMed Citation Articles by Extermann, M. Articles by Lyman, G. H.

What Threshold for Adjuvant Therapy in Older Breast Cancer Patients?

From the Senior Adult Oncology Program and Epidemiology and Biostatistics ProgramH. Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL.

Address reprint requests to Martine Extermann, MD, Senior Adult Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612; email extermann{at}moffitt.usf.edu

PURPOSE: To consider the question of when to prescribe adjuvant treatment for elderly breast cancer patients, particularly when comorbidities are present. Knowledge of the threshold relapse risks above which adjuvant treatment is worth prescribing would enhance decision making.

PATIENTS AND METHODS: A Markov analysis of data from the medical literature was conducted. Patients aged 65 to 85 years were considered, along with three levels of comorbidity. The threshold risk of relapse at 10 years (RR10), at which time treatment provides absolute reduction or reduction of an absolute 1% in relapse or mortality, was evaluated.

RESULTS: The threshold RR10 for an absolute reduction in mortality risk by adjuvant treatment was low through the age of 85 years. However, for an absolute 1% reduction, the effect of treatment on relapse and the effect of treatment on mortality increasingly diverged. The threshold RR10 for an absolute 1% reduction in relapse risk remained fairly low (5% to 6% for tamoxifen, 12% to 19% for chemotherapy). The threshold RR10 for an absolute 1% reduction in mortality risk, although starting close to the RR10 for an absolute 1% reduction in relapse risk, rose sharply. For tamoxifen, the difference between the two was 4% for an average 65-year-old, 6% at the age of 75 years, and 15% at the age of 85 years. For chemotherapy, the differences were 6%, 12%, and 30%, respectively. Similarly, thresholds increased with increasing comorbidity. In older and sicker patients, the maximum benefit was reached after 5 years rather than 10 years.

CONCLUSION: Older breast cancer patients can expect a reduction in relapse that is fairly similar to that of younger patients. However, the effect on mortality diverges markedly, and attention should be paid to this difference in clinical decision making. Comorbidity should be considered in recommendations for adjuvant treatment, including clinical practice guidelines.

This article has been cited by other articles:

				S. Dellapasqua, M. Colleoni, M. Castiglione, and A. Goldhirsch New Criteria for Selecting Elderly Patients for Breast Cancer Adjuvant Treatment Studies Oncologist, August 1, 2007; 12(8): 952 - 959. [Abstract] [Full Text] [PDF]

				G Mustacchi, M. Cazzaniga, P Pronzato, A De Matteis, F Di Costanzo, I Floriani, and On behalf of the NORA Study Group Breast cancer in elderly women: a different reality? Results from the NORA study Ann. Onc., June 1, 2007; 18(6): 991 - 996. [Abstract] [Full Text] [PDF]

				M. Extermann and A. Hurria Comprehensive Geriatric Assessment for Older Patients With Cancer J. Clin. Oncol., May 10, 2007; 25(14): 1824 - 1831. [Abstract] [Full Text] [PDF]

				D. Crivellari, M. Aapro, R. Leonard, G. von Minckwitz, E. Brain, A. Goldhirsch, A. Veronesi, and H. Muss Breast Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1882 - 1890. [Abstract] [Full Text] [PDF]

				M. B. Rodin and S. G. Mohile A Practical Approach to Geriatric Assessment in Oncology J. Clin. Oncol., May 10, 2007; 25(14): 1936 - 1944. [Abstract] [Full Text] [PDF]

				B. D. Smith, B. G. Haffty, A. Hurria, D. H. Galusha, and C. P. Gross Postmastectomy Radiation and Survival in Older Women With Breast Cancer J. Clin. Oncol., October 20, 2006; 24(30): 4901 - 4907. [Abstract] [Full Text] [PDF]

				D. A. Litvak and R. Arora Treatment of Elderly Breast Cancer Patients in a Community Hospital Setting Arch Surg, October 1, 2006; 141(10): 985 - 990. [Abstract] [Full Text] [PDF]

				S. Burdette-Radoux and H. B. Muss Adjuvant chemotherapy in the elderly: whom to treat, what regimen? Oncologist, March 1, 2006; 11(3): 234 - 242. [Abstract] [Full Text] [PDF]

				J. J. Doyle, A. I. Neugut, J. S. Jacobson, V. R. Grann, and D. L. Hershman Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study J. Clin. Oncol., December 1, 2005; 23(34): 8597 - 8605. [Abstract] [Full Text] [PDF]

				L. Balducci Squaring the Circle: Adjuvant Chemotherapy for Older Women With Breast Cancer J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2005; 60(9): 1135 - 1136. [Full Text] [PDF]

				A. Brunello, U. Basso, C. Pogliani, A. Jirillo, C. Ghiotto, H. Koussis, F. Lumachi, M. Iacobone, L. Vamvakas, and S. Monfardini Adjuvant chemotherapy for elderly patients (>=70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients Ann. Onc., August 1, 2005; 16(8): 1276 - 1282. [Abstract] [Full Text] [PDF]

				H. B. Muss, S. Woolf, D. Berry, C. Cirrincione, R. B. Weiss, D. Budman, W. C. Wood, I. C. Henderson, C. Hudis, E. Winer, et al. Adjuvant Chemotherapy in Older and Younger Women With Lymph Node-Positive Breast Cancer JAMA, March 2, 2005; 293(9): 1073 - 1081. [Abstract] [Full Text] [PDF]

				S. H. Giordano, G. N. Hortobagyi, S.-W. C. Kau, R. L. Theriault, and M. L. Bondy Breast Cancer Treatment Guidelines in Older Women J. Clin. Oncol., February 1, 2005; 23(4): 783 - 791. [Abstract] [Full Text] [PDF]

				G. H. Lyman, D. C. Dale, and J. Crawford Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices J. Clin. Oncol., December 15, 2003; 21(24): 4524 - 4531. [Abstract] [Full Text] [PDF]

				J. Mandelblatt, S. Saha, S. Teutsch, T. Hoerger, A. L. Siu, D. Atkins, J. Klein, M. Helfand, and for the Cost Work Group of the U.S. Preventive Ser The Cost-Effectiveness of Screening Mammography beyond Age 65 Years: A Systematic Review for the U.S. Preventive Services Task Force Ann Intern Med, November 18, 2003; 139(10): 835 - 842. [Abstract] [Full Text] [PDF]

				K. Monson, D. A. Litvak, and R. J. Bold Surgery in the Aged Population: Surgical Oncology Arch Surg, October 1, 2003; 138(10): 1061 - 1067. [Full Text] [PDF]

				M. Extermann, G. Albrand, H. Chen, S. Zanetta, R. Schonwetter, G. B. Zulian, A. Cantor, and J.-P. Droz Are Older French Patients As Willing As Older American Patients to Undertake Chemotherapy? J. Clin. Oncol., September 1, 2003; 21(17): 3214 - 3219. [Abstract] [Full Text] [PDF]

				C. E. Holmes and H. B. Muss Diagnosis and Treatment of Breast Cancer in the Elderly CA Cancer J Clin, July 1, 2003; 53(4): 227 - 244. [Abstract] [Full Text]

				K. W.L. Yee, J. L. Pater, L. Pho, B. Zee, and L. L. Siu Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier? J. Clin. Oncol., April 15, 2003; 21(8): 1618 - 1623. [Abstract] [Full Text] [PDF]

				R. A. Silliman, E. Guadagnoli, W. Rakowski, M. B. Landrum, T. L. Lash, R. Wolf, A. Fink, P. A. Ganz, J. Gurwitz, C. Borbas, et al. Adjuvant Tamoxifen Prescription in Women 65 Years and Older With Primary Breast Cancer J. Clin. Oncol., June 1, 2002; 20(11): 2680 - 2688. [Abstract] [Full Text] [PDF]

				National Institutes of Health Consensus Developmen National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 5 - 15. [Abstract] [Full Text] [PDF]

				H. B. Muss Factors Used to Select Adjuvant Therapy of Breast Cancer in the United States: an Overview of Age, Race, and Socioeconomic Status J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 52 - 55. [Abstract] [Full Text] [PDF]

				National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 J Natl Cancer Inst, July 4, 2001; 93(13): 979 - 989. [Abstract] [Full Text] [PDF]

				J. Mandelblatt, K. R. Yabroff, W. Lawrence, B. Yi, G. Orosz, H. G. Bloom, C. B. Schecther, M. Extermann, L. Balducci, W. Satadano, et al. Screening Mammography in Elderly Women JAMA, June 28, 2000; 283(24): 3202 - 3204. [Full Text] [PDF]